Suggested remit - To appraise the clinical and cost effectiveness of nivolumab with radiotherapy within its marketing authorisation for previously untreated glioblastoma multiforme
The company have informed NICE that the CM-498 clinical trial did not reach its primary endpoint. The company will not be applying for a marketing authorisation for this indication at this time. This appraisal is therefore suspended.
 
Status Suspended
Decision Selected
Process STA 2018
ID number 1562

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
19 July 2019 Suspended. The company have informed NICE that the CM-498 clinical trial did not reach its primary endpoint. The company will not be applying for a marketing authorisation for this indication at this time. This appraisal is therefore suspended.
21 February 2019 - 21 March 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 April 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual